KRYSTEXXA — Total revenues
Products & Services · Total revenuesAmgen KRYSTEXXA — Total revenues remained flat by 0.0% to $335.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.1%, from $296.25M to $335.00M. Over 2 years (FY 2023 to FY 2025), KRYSTEXXA — Total revenues shows an upward trend with a 122.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration, successful commercialization, or expanded patient access, while a decrease may signal increased competition, patent expiration, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales generated from the specific therapeutic product line within the company's p...
Peer comparison
Comparable to product-specific revenue reporting in other biotechnology or pharmaceutical firms, often benchmarked against the growth rates of similar specialty therapeutics or orphan drugs.
amgn_segment_krystexxa_total_revenuesHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $272.00M | $1.19B | $1.34B |
| YoY Change | — | +335.7% | +13.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's krystexxa — total revenues?
- Amgen (AMGN) reported krystexxa — total revenues of $335.00M in Q4 2025.
- How has Amgen's krystexxa — total revenues changed year-over-year?
- Amgen's krystexxa — total revenues increased by 13.1% year-over-year, from $296.25M to $335.00M.
- What is the long-term trend for Amgen's krystexxa — total revenues?
- Over 2 years (2023 to 2025), Amgen's krystexxa — total revenues has grown at a 122.0% compound annual growth rate (CAGR), from $272.00M to $1.34B.
- What does krystexxa — total revenues mean?
- The total revenue generated from sales of the KRYSTEXXA therapeutic product.